Cost-effectiveness of clozapine. A UK clinic-based study
Schizophrenia is highly expensive in calculable and incalculable costs. Measures which impact the cost in the most severely affected are likely to produce the greatest cost reductions. Studies regarding clozapine in the USA have demonstrated clear cost-effectiveness, despite the high prescription costs. There are no prior UK studies. We performed a cost-effectiveness analysis comparing the three years prior to commencing clozapine to the period following establishment of clozapine treatment (mean 36.4 months) for 26 patients with chronic schizophrenia or schizoaffective disorder. There was a significant improvement in all clinical ratings applied (and a mean net saving of ponds 3768 per annum). The cost-effectiveness of clozapine was double that of conventional neuroleptics (15.2 pre-, 33.0 post-clozapine, P < 0.005). As a naturalistic study our data provide valuable information on the cost-effectiveness of clozapine in the UK. Our methodology could be applied in a community setting or in the study of another atypical neuroleptic.
Five-year outcome and prognosis in schizophrenia: a report from the London Field Research Centre of the International Pilot Study of Schizophrenia
Comprehensive periodic health examination: impact on health care utilisation and costs in a working population in Japan
Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome
Evaluation of cytogenetic conversion to Ph- haemopoiesis in long-term bone marrow culture for patients with chronic myeloid leukaemia on conventional hydroxyurea therapy, on pulse high-dose hydroxyurea and on interferon-alpha
Effect of second-generation antipsychotics on employment and productivity in individuals with schizophrenia: an economic perspective
Modelling the impact of clozapine on suicide in patients with treatment-resistant schizophrenia in the UK
Determinants of work outcome in neuroleptic-resistant schizophrenia and schizoaffective disorder: cognitive impairment and clozapine treatment
Cost-effectiveness analysis of pharmacological treatments in schizophrenia: critical review of results and methodological issues
The practical management of refractory schizophrenia--the Maudsley Treatment REview and Assessment Team service approach
Variability of cost-effectiveness estimates for pharmaceuticals in Western Europe: lessons for inferring generalizability
Health care costs of therapy-refractory schizophrenic patients treated with clozapine: a study in a community psychiatric service in Italy
Costs and outcomes associated with an aripiprazole add-on or switching open-label study in psychosis
The health economic implications of treatment with quetiapine: an audit of long-term treatment for patients with chronic schizophrenia
Underprescribing of clozapine and unexplained variation in use across hospitals and regions in the Canadian province of Québec
A potential biomarker for treatment stratification in psychosis: evaluation of an [18F] FDOPA PET imaging approach.
Pharmacogenomics of Antidepressant and Antipsychotic Treatment: How Far Have We Got and Where Are We Going?
Comparison of sole nurse and team-delivered community clozapine services for people with treatment-resistant schizophrenia
Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here